Tags

Type your tag names separated by a space and hit enter

Screening for prostate cancer.
CA Cancer J Clin. 2009 Jul-Aug; 59(4):264-73.CC

Abstract

In the United States, prostate cancer will affect 1 man in 6 during his lifetime. Since the mid-1980s, screening with the prostate-specific antigen (PSA) blood test has more than doubled the risk of a prostate cancer diagnosis. A decrease in prostate cancer death rates has been observed since that time, but the relative contribution of PSA testing as opposed to other factors, such as improved treatment, has been uncertain. The recent release of 2 large randomized trials suggests that if there is a benefit of screening, it is, at best, small. Methods to assess a man's risk of prostate cancer, including those tools that integrate multiple risk factors, are now available and should be used in risk assessment. Men undergoing screening for prostate cancer may reduce their risk of prostate cancer with finasteride.

Authors+Show Affiliations

American Cancer Society, Atlanta, GA, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19564245

Citation

Brawley, Otis W., et al. "Screening for Prostate Cancer." CA: a Cancer Journal for Clinicians, vol. 59, no. 4, 2009, pp. 264-73.
Brawley OW, Ankerst DP, Thompson IM. Screening for prostate cancer. CA Cancer J Clin. 2009;59(4):264-73.
Brawley, O. W., Ankerst, D. P., & Thompson, I. M. (2009). Screening for prostate cancer. CA: a Cancer Journal for Clinicians, 59(4), 264-73. https://doi.org/10.3322/caac.20026
Brawley OW, Ankerst DP, Thompson IM. Screening for Prostate Cancer. CA Cancer J Clin. 2009 Jul-Aug;59(4):264-73. PubMed PMID: 19564245.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Screening for prostate cancer. AU - Brawley,Otis W, AU - Ankerst,Donna P, AU - Thompson,Ian M, Y1 - 2009/06/29/ PY - 2009/7/1/entrez PY - 2009/7/1/pubmed PY - 2009/8/6/medline SP - 264 EP - 73 JF - CA: a cancer journal for clinicians JO - CA Cancer J Clin VL - 59 IS - 4 N2 - In the United States, prostate cancer will affect 1 man in 6 during his lifetime. Since the mid-1980s, screening with the prostate-specific antigen (PSA) blood test has more than doubled the risk of a prostate cancer diagnosis. A decrease in prostate cancer death rates has been observed since that time, but the relative contribution of PSA testing as opposed to other factors, such as improved treatment, has been uncertain. The recent release of 2 large randomized trials suggests that if there is a benefit of screening, it is, at best, small. Methods to assess a man's risk of prostate cancer, including those tools that integrate multiple risk factors, are now available and should be used in risk assessment. Men undergoing screening for prostate cancer may reduce their risk of prostate cancer with finasteride. SN - 0007-9235 UR - https://www.unboundmedicine.com/medline/citation/19564245/Screening_for_prostate_cancer_ L2 - https://doi.org/10.3322/caac.20026 DB - PRIME DP - Unbound Medicine ER -